A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Фаза 3
Завершено
NCT05514535
| Заболевание | Diabetes Mellitus, Type 2, Obesity |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Novo Nordisk A/S |
|---|
| Статус | Завершено |
|---|
| Участники | 573 участн. |
|---|
| Вмешательство | Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated) |
|---|
| Дата начала | 29.08.2022 |
|---|
| Дата завершения | 5.03.2025 |
|---|
| Публикация результатов | 11.05.2026 |
|---|
Кратко
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.
Change in Glycated Haemoglobin (HbA1c) [Noninferiority]
From baseline (week 0) to end of treatment (week 40) · Percentage point of HbA1c
| Insuline Glargine U100 (Reduced) + Semaglutide | -1.37 ± 0.84 Percentage point of HbA1c |
|---|
| Insuline Glargine U100 (Titrated) | -0.65 ± 0.92 Percentage point of HbA1c |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.